← All events
Markets·Unverified·Live
Gilead agreed to buy private German biotech Tubulis in a deal worth up to $5 billion to boost its cancer drug development portfolio.
Updated ·First reported
Developing — full summary pending.
Gilead agreed to buy private German biotech Tubulis in a deal worth up to $5 billion to boost its cancer drug development portfolio.
Locations
GermanyGermany, Europe
51.17, 10.45